HEAL-LAA Clinical Trial

Inclusion Criteria:

• Subject is of legal age to participate in the study.

• Subject has documented non-valvular atrial fibrillation (i.e., atrial fibrillationin the absence of moderate or greater mitral stenosis or a mechanical heart valve).

• Subject is clinically indicated for and is treated or attempted to be treated with aWATCHMAN FLX™ Pro device.

• Subject or legal representative is able to understand and willing to provide writteninformed consent to participate in the study.

• Subject is able and willing to return for required follow-up visits andexaminations.

Exclusion Criteria:

• Subject has a documented life expectancy of less than 6 months.

• Subject is currently enrolled in another investigational study, except if thesubject is participating in a mandatory governmental registry, or a purelyobservational registry with no associated treatment.

• Intracardiac thrombus is present.

• An atrial septal defect repair or closure device or a patent foramen ovale repair orclosure device is present.

• The LAA anatomy will not accommodate a Closure Device.

• The patient has known hypersensitivity to any portion of the device material or theindividual components such that the use of the WATCHMAN FLX™ Pro Device iscontraindicated.

• Any of the customary contraindications for other percutaneous catheterizationprocedure (e.g., patient size too small to accommodate transesophagealechocardiography (TEE) probe or required catheters) or conditions (e.g., activeinfection, bleeding disorder) are present.

• There are contraindications to the use of anticoagulation therapy, aspirin, or P2Y12inhibitor.

• Subject is of childbearing potential and is, or plans to become, pregnant during thetime of the study (method of assessment per study physician's discretion).